Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 4/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 5/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL29380342 | 0.89 | PTPN7 (0.45) | HMGCRPTPN7RECQLTDP1ACE2 | |
| SCHEMBL272762 | 0.84 | ACE2 (0.44) | ACE2GPR84FFAR1MAPT | |
| SCHEMBL29528259 | 0.82 | HMGCR (0.41) | HMGCRPTPN7RECQLTDP1ACE2 | |
| SCHEMBL273813 | 0.79 | CA2 (0.42) | ACE2GPR84FFAR1MAPT | |
| Bicarbonate SCHEMBL30656137 | 0.79 | PTPN7 (0.61) | HMGCRPTPN7RECQLTDP1GPR84 | |
| Bicarbonate SCHEMBL874695 | 0.79 | PTPN7 (0.61) | HMGCRPTPN7RECQLTDP1GPR84 | |
| SCHEMBL29402864 | 0.78 | HMGCR (0.36) | HMGCRPTPN7RECQLTDP1KDM4E | |
| Bicarbonate SCHEMBL28077752 | 0.78 | PTPN7 (0.59) | HMGCRPTPN7RECQLTDP1GPR84 | |
| Bicarbonate SCHEMBL873829 | 0.78 | HMGCR (0.57) | HMGCRPTPN7RECQLTDP1GPR84 | |
| SCHEMBL2320188 | 0.76 | ACE2 (0.43) | ACE2GPR84FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | GIVAUDAN SA (CH) | 2026-03-31 | — | — | US | disclosed |
| EP-4709515-A1 | COMPOSITION | Givaudan SA (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-12559703-B2 | Fragrance composition | GIVAUDAN SA (CH) | 2026-02-24 | — | — | US | disclosed |
| US-12539261-B2 | Encapsulated compositions | GIVAUDAN SA (CH) | 2026-02-03 | — | — | US | disclosed |
| US-20250387771-A1 | COMPOSITION COMPRISING BIODEGRADABLE MICROCAPSULES | GIVAUDAN SA (CH) | 2025-12-25 | — | — | US | disclosed |
| EP-4658741-A1 | LAUNDRY CARE COMPOSITION | Givaudan SA (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250345251-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2025-11-13 | — | — | US | disclosed |
| US-20250332085-A1 | RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4637984-A1 | MICROCAPSULES | Givaudan SA (CH) | 2025-10-29 | — | — | EP | disclosed |
| EP-4626594-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2025-10-08 | — | — | EP | disclosed |
| US-11434448-B2 | Perfume compositions | GIVAUDAN S.A. (CH) | 2022-09-06 | — | — | US | disclosed |
| WO-2022175314-A1 | IMPROVEMENT IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2022-08-25 | — | — | WO | disclosed |
| US-11382845-B2 | Organic compounds | GIVAUDAN SA (CH) | 2022-07-12 | — | — | US | disclosed |
| EP-4021629-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2022-07-06 | — | — | EP | disclosed |
| US-20220202665-A1 | CORE-SHELL ENCAPSULATE COMPOSITION COMPRISING A BENEFIT AGENT | GIVAUDAN SA (CH) | 2022-06-30 | — | — | US | disclosed |
| WO-2022112204-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2022-06-02 | — | — | WO | disclosed |
| US-20220151902-A1 | ENCAPSULATED COMPOSITION | GIVAUDAN SA (CH) | 2022-05-19 | — | — | US | disclosed |
| US-20220110853-A1 | IMPROVEMENT IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2022-04-14 | — | — | US | disclosed |
| EP-3972554-A1 | CORE-SHELL ENCAPSULATED COMPOSITION COMPRISING A BENEFIT AGENT | Givaudan SA (CH) | 2022-03-30 | — | — | EP | disclosed |
| US-20220041569-A1 | (3aS,4aR,5S,7aS,9R,9aR)-2,2,5,8,8,9a-hexamethyloctahydro-4H-4a,9-methanoazuleno[5,6-d][1,3]dioxole | GIVAUDAN S.A. (CH) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151902-A1 | ENCAPSULATED COMPOSITION | PHOSPHO1, CUTA, S100A10 | HMGCR 4010/4885PTPN7 3929/4885RECQL 1134/4885 |
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | CUTA, EXOC1, EXOSC10 | HMGCR 3945/4885PTPN7 2707/4885RECQL 2976/4885 |
| US-20250387771-A1 | COMPOSITION COMPRISING BIODEGRADABLE MICROCAPSULES | LCT, LPO, RCC1 | HMGCR 1987/4885PTPN7 2253/4885RECQL 1354/4885 |
| US-12559703-B2 | Fragrance composition | DHCR24, OPRD1, OR10J3 | HMGCR 874/4885PTPN7 4151/4885RECQL 4466/4885 |
| US-20220202665-A1 | CORE-SHELL ENCAPSULATE COMPOSITION COMPRISING A BENEFIT AGENT | PHOSPHO1, CUTA, AAAS | HMGCR 2759/4885PTPN7 4434/4885RECQL 2173/4885 |
| US-20220041569-A1 | (3aS,4aR,5S,7aS,9R,9aR)-2,2,5,8,8,9a-hexamethyloctahydro-4H-4a,9-methanoazuleno[5,6-d][1,3]dioxole | DHRS9, MSMO1, CYP4X1 | HMGCR 264/4885PTPN7 2608/4885RECQL 999/4885 |
| US-12539261-B2 | Encapsulated compositions | ALG1, GNE, ILK | HMGCR 719/4885PTPN7 4807/4885RECQL 2944/4885 |
| US-20250345251-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | TRPM5, KCNN2, MLEC | HMGCR 2605/4885PTPN7 3493/4885RECQL 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.